#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Pandemic of hepatitis C virus infection


Authors: M. Dyrhonová 1,2;  R. Chlíbek 1
Authors place of work: Katedra epidemiologie, Fakulta vojenského zdravotnictví Univerzity obrany, Hradec Králové 1;  Infekční oddělení, Mělnická zdravotní, a. s. 2
Published in the journal: Epidemiol. Mikrobiol. Imunol. 65, 2016, č. 2, s. 72-78
Category: Review Article

Summary

Hepatitis C virus (HCV) is an important human pathogen that causes hepatitis, advanced liver fibrosis, cirrhosis (CIH), and hepatocellular carcinoma (HCC). Especially the chronic form of hepatitis C (HC), with 55–85% of acute cases progressing to it, is a serious problem worldwide. HCV is a cause of the significant morbidity and mortality that are only expected to peak. An ongoing research of new therapeutic molecules for the treatment of HCV infection is a promise for a better future. The costs incurred are, however, high.

Key words:
hepatitis C – genotypes – prevalence – risk groups – HCV-associated diseases


Zdroje

1. Beeson PB. Jaundice occurring one to four months after transfusion of blood or plasma. Report of seven cases. JAMA, 1943;121:1332–1334.

2. Ezzell C. Nature News – Candidate cause identified of non-A, non-B hepatitis. Nature, 1988;333:195.

3. Catanese MT, Uryu K, Kopp M, et al. Ultrastructural analysis of hepatitis C virus particles. Proc Natl Acad Sci USA, 2013;110:9505–9510.

4. Vieyres G, Dubuisson J, Pietschmann T. Incorporation of hepatitis C virus E1 and E2 glycoproteins: the keystones on a peculiar virion. Viruses, 2014;6:1149–1187.

5. Husa P. Virové hepatitidy. 1. vyd. Praha: Galén; 2005, 247 s. ISBN 80-726-2304-4.

6. Meex SJ, Andreo U, Sparks JD, et al. Huh-7 or HepG2 cells: which is the better model for studying human apolipoprotein-B100 assembly and secretion? J Lipid Res, 2011;52:152–158.

7. Lagaye S, Shen H, Saunier B, et al. Efficient replication of primary or culture hepatitis C virus isolates in human liver slices: a relevant ex vivo model of liver infection. Hepatology, 2012;56:861–872.

8. Ploss A, Khetani SR, Jones CT, et al. Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures. Proc Natl Acad Sci USA, 2010;107:3141–3145.

9. Podevin P, Carpentier A, Pene V, et al. Production of infectious hepatitis C virus in primary cultures of human adult hepatocytes. Gastroenterology, 2010;139:1355–1364.

10. Merz A, Long G, Hiet M-S, et al. Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome. J Biol Chem, 2011;286:3018–3032.

11. Baumert TF, Zeuzem S, Overcoming the roadblocks in hepatitis C virus infection. J Hepatol, 2014;61(1), Supplement, S1–S2.

12. Douam F, Dao Thi VL, Maurin G, et al. Critical interaction between E1 and E2 glycoproteins determines binding and fusion properties of hepatitis C virus during cell entry. Hepatology, 2014;59:776–788.

13. Lavillette D, Pécheur EI, Donot P, et al. Characterization of fusion determinants points to the involvement of three discrete regions of both E1 and E2 glycoproteins in the membrane fusion proces of hepatitis C virus. J Virol, 2007;81(16):8752–8765.

14. Lefèvre M, Felmlee DJ, Parnot M, et al. Syndecan 4 is involved in mediating HCV entry through interaction with lipoviral particle-associated apolipoprotein E. PLoS ONE, 2014;9(4): e95550. doi: 10.1371/journal.pone.0095550.

15. Shi Q, Jiang J, Luo G. Syndecan-1 serves as the major receptor for attachment of hepatitis C virus to the surfaces of hepatocytes. J Virol, 2013;87:6866–6875.

16. Dao Thi VL, Granier C, Zeisel MB, et al. Characterization of hepatitis C virus particle sub-populations reveals multiple usage of the scavenger receptor B1 entry steps. J Biol Chem, 2012;287:31242–31257.

17. Jiang J, Wu X, Tang H et al. Apolipoprotein E mediates attachment of clinical hepatitis C virus to hepatocytes by binding to cell surface heparan sulfate proteoglycan receptors. PLoS ONE, 2013;8(7): e67982. doi: 10.1371/journal.pone.0067982.

18. Albecka A, Belouzard S, de Beeck AO, et al. Role of low-density lipoprotein receptor in the hepatitis C virus life cycle. Hepatology, 2012;55:998–1007. doi: 10.1002/hep.25501.

19. Scarselli E, Ansuini H, Cerino R, et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J, 2002;21:5017–5025.

20. Pileri P, Uematsu Y, Campagnoli S, et al. Binding of hepatitis C virus to CD81. Science, 1998;282:938–941.

21. Evans MJ, von Hahn T, Tscherne DM, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature, 2007;446:801–805.

22. Ploss A, Evans MJ, Gaysinskaya VA, et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature, 2009;457:882–886.

23. Fénéant L, Levy S, Cocquerel L. CD81 and hepatitis C virus (HCV) infection. Viruses, 2014;6(2):535–572.

24. Fletcher NF, Sutaria R, Jo J, et al. Activated macrophages promote hepatitis C virus entry in a tumor necrosis factor-dependent manner. Hepatology, 2014;59:1320–1330. doi: 10.1002/hep.26911.

25. Dubuisson J, Cosset FL. Virology and cell biology of the hepatitis C virus life cycle – An update. J Hepatol, 2014; 61(1), S3–S13. doi: 10.1016/j.jhep.2014.06.031.

26. Bartenschlager R, Lohmann V, Penin F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol, 2013;11:482–496. doi:10.1038/nrmicro3046.

27. Wieland S, Makowska Z, Campana B, et al. Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver. Hepatology, 2014;59:2121–2130.

28. Horák J. Akutní a chronická hepatitida. Postgraduální medicína, 2001;3(1):8–10.

29. Martell M, Esteban JI, Quer J, et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol, 1992;66:3225–3229.

30. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut, 2006;55:1350–1359. doi: 10.1136/gut.2005.076646.

31. Zein NN. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev, 2000;13:223–235.

32. Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology, 2013;57:1333–1342. doi: 10.1002/hep.26141.

33. Messina JP, Humphreys I, Flaxman A, et al. Global Distribution and Prevalence of Hepatitis C Virus Genotypes. Hepatology, 2015;61(1):77–87. doi:10.1002/hep.27259.

34. Razavi H, Elkhoury AC, Elbasha E, et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology, 2013;57:2164–2170. doi: 10.1002/hep.26218

35. Collaborators (52). Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996–2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis, 2010;50:1387–1396.

36. Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide, J Hepatol, 2006;45:529–538.

37. Negro F. Epidemiology of hepatitis C in Europe, Digestive and Liver Disease, 2014;46 (Suppl5): S158–S164. doi: 10.1016/j.dld.2014.09.023.

38. Ly KN, Xing J, Liu SJ, et al. Causes of death and characteristics of decedents with viral hepatitis, United States, 2010. Clin Infect Dis, 2014;58:40–49.

39. Cowie BC, Allard N, MacLachlan JH. European responses in focus: comparing viral hepatitis and HIV related deaths in Europe 1990–2001 in the Global Burden of Disease Study 2010. in: 49th Annual meeting of the European association for the study of the liver.; 2014 (abstract #86).

40. Garcia-Fulgueiras A, Garcia-Pina R, Morant C, et al. Burden of disease related to hepatitis C and hepatitis B in Spain: a methodological challenge of an unfolding health problém. J Viral Hepatitis, 2011;18: e453–e460.

41. Marcellin P, Pequignot F, Delarocque-Astagneau E, et al. Mortality related to chronic hepatitis B a chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. J Hepatol, 2008;48:200–207.

42. Lee MH, Yang HI, Lu SN, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis, 2012;206: 469–477.

43. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA, 2012;308(24):2584–2593.

44. Hsu YC, Lin JT, Ho HJ, et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology, 2014;59:1293–1302.

45. Hsu CS, Kao JH, Chao YC, et al. Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan. Aliment Pharmacol Ther, 2013;38:415–423.

46. Razavi H, Waked I, Sarrazin C, et al. The present and future disease burden of hepatitis C virus with today´s treatment paradigm. J Viral Hepat 2014;21(Suppl.1): 34–59. doi: 10.1111/jvh.12248.

47. Chlíbek R. Virová hepatitida C v ordinaci praktického lékaře. Practicus, 2014;8:14–15. Dostupný na www: <http://web.practicus.eu/sites/cz/Documents/Practicus-2014-10/14-Hepatitida-C.pdf>

48. Státní zdravotní ústav. Infekce v ČR – EPIDAT. Dostupný na www: <http://www.szu.cz/publikace/data/infekce-v-cr>

49. Thomas HC, Lok ASF, Locarnini SA, et al. Viral hepatitis. Fourth edition. 2014. John Wiley&Sons Ltd. ISBN: 978-0-470-67295-2.

50. Trunečka P. Transplantace jater – kdo a kdy…ZN, Lékařské listy, 2013;6. Dostupný na www: http://zdravi.e15.cz/clanek/priloha-lekarske-listy/transplantace-jater-kdo-a-kdy-471004.

51. Simmonds P, Alberti A, Alter HJ, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology, 1994;19:1321–1324.

52. Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology, 2014;59(1):318–327. doi: 10.1002/hep.26744.

53. Smith DB, Pathirana S, Davidson F, et al. The origin of hepatitis C virus genotypes. J Gen Virol, 1997;78(Pt 2):321–328.

54. Pybus OG, Cochrane A, Holmes EC, et al. The hepatitis C virus epidemic among injecting drug users. Infect Genet Evol, 2005;5:131–139.

55. Magiorkinis G, Magiorkinis E, Paraskevis D, et al. The global spread of hepatitis C virus 1a and 1b: a phylodynamic and phylogeographic analysis. PLoS Med, 2009;6(12): e1000198. doi:10.1371/journal.pmed.1000198.

56. Murphy DG, Willems B, Deschenes M, et al. Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5' untranslated region sequences. J Clin Microbiol, 2007;45:1102–1112.

57. de Lédinghen V, Trimoulet P, Mannant PR, et al. Outbreak of hepatitis C virus infection during sclerotherapy of varicose veins: long-term follow-up of 196 patients (4535 patient-years). J Hepatol, 2007;46:19–25.

58. Sauné K, Kamar N, Miédougé M, et al. Decreased prevalence and incidence of HCV markers in haemodialysis units: a multicentric French survey. Nephrology, Dialysis, Transplantation, 2011; 26:2309–2316.

59. Marco A, Esteban JI, Solé C, et al. Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C. J Hepatol, 2013;59:45–51.

60. Bertoletti A, Ferrari C, Kinetics of the immune response during HBV and HCV infection. Hepatology, 2003;38:4–13.

61. Chalupa P, Holub M, Davidová A, et al. Imunitní odpověď v patogenezi infekce virem hepatitidy C. Epidemiol Mikrobiol Imunol, 2015;64(4):198–203.

62. Heim MH, Thimme R. Innate and adaptive immune responses in HCV infections. J Hepatol, 2014; 61(1) Supplement: S14–S25.

63. Santantonio T, Wiegand J, Gerlach JT. Acute hepatitis C: current status and remaining challenges. J Hepatol, 2008;49(4):625–633. doi: 10.1016/j.jhep.2008.07.005.

64. Urbánek P, Husa P, Šperl J, et al. Standardní diagnostický a terapeutický postup chronické infekce virem hepatitidy C (HCV), srpen 2015. Dostupné na www: <http://www.ceshep.cz/file/415/guidelines-hcv-2015-chs--sil.pdf>

65. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med, 2001;345(1):41–52.

66. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology, 2012;142(6): 1264–1273,e1. doi: 10.1053/j.gastro.2011.12.061.

67. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med, 1986;315:1575–1578.

68. Ciesek S, Friesland M, Steinmann J, et al. How stable is the hepatitis C virus (HCV)? Environmental stability of HCV and its susceptibility to chemical biocides. J Infect Dis, 2010; 201:1859–1866.

69. Mravčík V, Strada L, Reimer J, et al. Hepatitis C treatment uptake and adherence among injecting drug users in the Czech Republic. Epidemiol Microbiol Imunol, 2014;63(4):265–269.

70. Baumert TF, Fauvelle C, Chen DY, et al. A prophylactic hepatitis C virus vaccine: A distant peak still worth climbing. J Hepatol, 2014; 61(1)Supplement:S34–S44.

Štítky
Hygiene and epidemiology Medical virology Clinical microbiology

Článok vyšiel v časopise

Epidemiology, Microbiology, Immunology

Číslo 2

2016 Číslo 2

Najčítanejšie v tomto čísle
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#